Trials / Not Yet Recruiting
Not Yet RecruitingNCT05747716
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody Cadonilimab for Third-line Treatment in Metastatic Colonrectal Cancer.
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is a phase II clinical study. The purpose of the study is to evaluate the efficacy and safety of SBRT combined with Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBRT, Fruquintinib, Cadonilimab | Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2023-02-28
- Last updated
- 2023-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05747716. Inclusion in this directory is not an endorsement.